{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T06:20:06Z","timestamp":1777702806317,"version":"3.51.4"},"reference-count":17,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.ahj.2011.08.004","type":"journal-article","created":{"date-parts":[[2011,9,15]],"date-time":"2011-09-15T20:14:24Z","timestamp":1316117664000},"page":"620-626.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":122,"title":["EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE)"],"prefix":"10.1016","volume":"162","clinical-trial-number":[{"clinical-trial-number":"nct00968708","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"William B.","family":"White","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George L.","family":"Bakris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard M.","family":"Bergenstal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher P.","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William C.","family":"Cushman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Penny","family":"Fleck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Heller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyrus","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven E.","family":"Nissen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"suppl 2","key":"10.1016\/j.ahj.2011.08.004_bb0005","doi-asserted-by":"crossref","first-page":"S358","DOI":"10.1007\/s00592-003-0120-0","article-title":"Epidemiology of cardiovascular complications in type 2 diabetes mellitus","volume":"40","author":"Meigs","year":"2003","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.ahj.2011.08.004_bb0010","series-title":"National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007","author":"Centers for Disease Control and Prevention (CDC)","year":"2008"},{"key":"10.1016\/j.ahj.2011.08.004_bb0015","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS-33)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2011.08.004_bb0020","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa1006524","article-title":"Long-term effects of intensive glucose lowering on cardiovascular outcomes","volume":"364","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2011.08.004_bb0025","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2011.08.004_bb0030","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMp0805758","article-title":"Assessing the cardiovascular safety of diabetes therapies","volume":"359","author":"Goldfine","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2011.08.004_bb0035","author":"U.S. Food and Drug Administration"},{"key":"10.1016\/j.ahj.2011.08.004_bb0040","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2337\/diabetes.47.11.1663","article-title":"Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes","volume":"47","author":"Holst","year":"1998","journal-title":"Diabetes"},{"key":"10.1016\/j.ahj.2011.08.004_bb0045","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2174\/157339910793499119","article-title":"Alogliptin: a novel molecule for improving glycemic control in type II diabetes mellitus","volume":"6","author":"Ghatak","year":"2010","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.ahj.2011.08.004_bb0050","article-title":"Cardiovascular events in patients receiving alogliptin: findings from a pooled analysis of randomized clinical trials","author":"White","year":"2010"},{"key":"10.1016\/j.ahj.2011.08.004_bb0055","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2307\/2336502","article-title":"Discrete sequential boundaries for clinical trials","volume":"70","author":"Lan","year":"1983","journal-title":"Biometrika"},{"key":"10.1016\/j.ahj.2011.08.004_bb0060","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/sim.4780081003","article-title":"Group sequential procedures: calendar versus information time","volume":"8","author":"Lan","year":"1989","journal-title":"Stat Med"},{"key":"10.1016\/j.ahj.2011.08.004_bb0065","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1093\/eurheartj\/ehm209","article-title":"Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval","volume":"28","author":"Borer","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2011.08.004_bb0070","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2165\/0002512-200825110-00002","article-title":"New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies","volume":"25","author":"Abbatecola","year":"2008","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ahj.2011.08.004_bb0075","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1093\/eurheartj\/ehl220","article-title":"Acute coronary syndromes and diabetes: Is intensive lipid lowering beneficial? Results from the PROVE-IT-TIMI 22 trial","volume":"27","author":"Ahmed","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2011.08.004_bb0080","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1161\/CIRCULATIONAHA.108.791061","article-title":"Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-TIMI 38","volume":"118","author":"Wiviott","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2011.08.004_bb0085","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.ahj.2007.11.029","article-title":"Effects of pioglitazone on major adverse events in high-risk patients with type 2 diabetes: results from PROspective pioglitazone Clinical Trial In macroVascular Events (PROactive 10)","volume":"155","author":"Wilcox","year":"2008","journal-title":"Am Heart J"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870311005758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870311005758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:46:00Z","timestamp":1757569560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870311005758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0002870311005758"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2011.08.004","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE)","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2011.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Mosby, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}